Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
出版年份 2021 全文链接
标题
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
作者
关键词
PI3K/Akt/mTOR signaling, Human cancer, Hyperactivation, Targeted therapy, Inhibitors, Combination therapy, Biomarker
出版物
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-06-25
DOI
10.1016/j.semcancer.2021.06.019
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Preclinical evaluation and Phase 1b study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor
- (2021) David S. Hong et al. CLINICAL CANCER RESEARCH
- Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
- (2021) Yu-xiang Wang et al. Cell Death & Disease
- Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
- (2021) Jian Wang et al. Oncogenesis
- The Roles of Post-Translational Modifications on mTOR Signaling
- (2021) Shasha Yin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
- (2021) Neel D. Trivedi et al. Cancer Medicine
- SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
- (2021) Xi Zhang et al. ACTA PHARMACOLOGICA SINICA
- Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients
- (2020) Wang Jiangyi et al. Aging-US
- A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration resistant prostate cancer.
- (2020) M.P. Kolinsky et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
- (2020) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PIK3CA gene aberrancy and role in targeted therapy of solid malignancies
- (2020) Owen Willis et al. CANCER GENE THERAPY
- First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma
- (2020) Patrick Y. Wen et al. CLINICAL CANCER RESEARCH
- Wnt/beta-catenin and PI3K/Akt/mtor Signaling Pathways in Glioblastoma: Two main targets for drug design: A Review
- (2020) Seyed Hossein Shahcheraghi et al. CURRENT PHARMACEUTICAL DESIGN
- Isoform-Selective PI3K Inhibitors for Various Diseases
- (2020) Rammohan R. Yadav Bheemanaboina CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
- (2020) Binquan Wu et al. Expert Opinion on Drug Delivery
- Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
- (2020) F. Coussy et al. Journal of Hematology & Oncology
- Targeting AKT/PKB to improve treatment outcomes for solid tumors
- (2020) M. Iida et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control
- (2020) Wenjian Gan et al. NATURE CELL BIOLOGY
- mTOR at the nexus of nutrition, growth, ageing and disease
- (2020) Grace Y. Liu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
- (2020) Fan Li et al. ONCOGENE
- Copanlisib: Novel PI3K Inhibitor for Treatment of Lymphoma.
- (2020) Anshul Kumar et al. Anti-Cancer Agents in Medicinal Chemistry
- A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
- (2020) Eleftherios Kostaras et al. BRITISH JOURNAL OF CANCER
- A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
- (2020) Mojun Zhu et al. INVESTIGATIONAL NEW DRUGS
- Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
- (2020) Nicci Owusu-Brackett et al. Oncotarget
- Exosomal miR-21 promotes proliferation, invasion and therapy resistance of colon adenocarcinoma cells through its target PDCD4
- (2020) Li-Hua Sun et al. Scientific Reports
- Targeting PIK3CG in Combination with Paclitaxel as a Potential Therapeutic Regimen in Claudin-Low Breast Cancer
- (2020) Jun Chang et al. Cancer Management and Research
- First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
- (2020) Robert McLeod et al. CLINICAL CANCER RESEARCH
- Copanlisib in the treatment of non-Hodgkin lymphoma
- (2020) Mayur Narkhede et al. Future Oncology
- Nanotechnology-Based Targeting of mTOR Signaling in Cancer
- (2020) Mee-Sup Yoon International Journal of Nanomedicine
- Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene
- (2020) Kai Chen et al. LIFE SCIENCES
- STAT3‐mediated MLST8 gene expression regulates cap‐dependent translation in cancer cells
- (2020) Hyunji Lee et al. Molecular Oncology
- Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells
- (2020) Mohamed E. Abdallah et al. MOLECULES
- cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy
- (2020) Wenwen Li et al. Science Translational Medicine
- AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway
- (2020) Lun Gao et al. Frontiers in Pharmacology
- Experimental Approaches in Delineating mTOR Signaling
- (2020) Jiayi Qian et al. Genes
- Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
- (2020) Douglas K. Marks et al. Frontiers in Oncology
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
- (2020) Hye Ryun Kim et al. BRITISH JOURNAL OF CANCER
- Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer
- (2020) Susana Ros et al. CANCER CELL
- Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance
- (2020) Tzu-Ting Huang et al. CANCER RESEARCH
- mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
- (2020) Niklas Gremke et al. Nature Communications
- Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
- (2020) Monique Bernard et al. Cancers
- Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
- (2020) Ying Chen et al. Frontiers in Cell and Developmental Biology
- PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
- (2020) Sadegh Fattahi et al. LIFE SCIENCES
- Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4 /6 Inhibitor Therapy
- (2020) Madeline M. Cook et al. ONCOLOGIST
- Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
- (2020) Yumi Fujimoto et al. Scientific Reports
- Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
- (2020) Shu Wang et al. Biomed Research International
- SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia
- (2020) Lei Fan et al. NEOPLASIA
- Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
- (2020) S. Dent et al. ANNALS OF ONCOLOGY
- Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
- (2019) Takuro Yamamoto et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer
- (2019) Angela Esposito et al. JAMA Oncology
- Identification of recurrent fusion genes across multiple cancer types
- (2019) Yan-Ping Yu et al. Scientific Reports
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- Patient-driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-driven Cancer
- (2019) Emily K Slotkin et al. Cancer Discovery
- Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
- (2019) Carolina Caro-Vegas et al. mBio
- Mechanisms of PTEN loss in cancer: It’s all about diversity
- (2019) Virginia Álvarez-Garcia et al. SEMINARS IN CANCER BIOLOGY
- PTEN arginine methylation by PRMT6 suppresses PI3K–AKT signaling and modulates pre-mRNA splicing
- (2019) Jiawen Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Control of mTOR signaling by ubiquitin
- (2019) Yao Jiang et al. ONCOGENE
- Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer
- (2019) Xiaobing Shen et al. Future Oncology
- Cell migration and proliferation are regulated by miR-26a in colorectal cancer via the PTEN–AKT axis
- (2019) Jossimar Coronel-Hernández et al. Cancer Cell International
- Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy
- (2019) Yeying Liu et al. Cancer Cell International
- PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells
- (2019) Felicitas Bossler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
- (2019) Geoffrey I. Shapiro et al. INVESTIGATIONAL NEW DRUGS
- Paired Genomic Analysis of Squamous Cell Carcinoma Transformed From EGFR-mutated Lung Adenocarcinoma
- (2019) Sehhoon Park et al. LUNG CANCER
- PI3K isoforms in cell signalling and vesicle trafficking
- (2019) Benoit Bilanges et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
- (2019) Yi-Hui Wu et al. Cell Death & Disease
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II
- (2019) Shanshan Zhao et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features
- (2019) Qingqing Ding et al. HUMAN PATHOLOGY
- Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
- (2019) Corey J. Langer et al. Journal of Thoracic Oncology
- Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging
- (2019) Yiming Li et al. NEURORADIOLOGY
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- (2019) Hang Zhao et al. OncoTargets and Therapy
- MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
- (2019) Yao Jiang et al. Nature Communications
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
- (2019) Richard D. Baird et al. CLINICAL CANCER RESEARCH
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors
- (2019) Xueqiong Zhang et al. JOURNAL OF CONTROLLED RELEASE
- A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1
- (2019) Xin Xia et al. Molecular Cancer
- A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
- (2019) Edward Wolin et al. PLoS One
- mTOR: Role in cancer, metastasis and drug resistance
- (2019) Avaniyapuram Kannan Murugan SEMINARS IN CANCER BIOLOGY
- Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
- (2019) M Brandão et al. ANNALS OF ONCOLOGY
- Distinct functions of AKT isoforms in breast cancer: a comprehensive review
- (2019) Nico Hinz et al. Cell Communication and Signaling
- Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency
- (2019) Chien-Ju Chen et al. NATURE MEDICINE
- Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- (2019) Neil Vasan et al. SCIENCE
- Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation
- (2019) Joséphine Briand et al. Clinical Epigenetics
- FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland
- (2019) Yasuhiro Isono et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
- (2019) Andrea P. Myers et al. INTERNATIONAL JOURNAL OF CANCER
- Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia
- (2019) Steven T. Bird et al. JAMA Oncology
- Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer
- (2018) Troels Dreier Christensen et al. ACTA ONCOLOGICA
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia
- (2018) Bahareh Toosi et al. BIOMEDICINE & PHARMACOTHERAPY
- MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer
- (2018) Manxin Xie et al. BIOMEDICINE & PHARMACOTHERAPY
- Overexpression of long non-coding RNA H19 promotes invasion and autophagy via the PI3K/AKT/mTOR pathways in trophoblast cells
- (2018) Jin Xu et al. BIOMEDICINE & PHARMACOTHERAPY
- An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation
- (2018) Jeffrey J. Heard et al. BMC CANCER
- Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
- (2018) Karineh Petrossian et al. BREAST CANCER RESEARCH AND TREATMENT
- Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer
- (2018) Xue-ling Liu et al. CANCER LETTERS
- Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
- (2018) Hideki Makinoshima et al. CANCER RESEARCH
- Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
- (2018) Maura N. Dickler et al. CLINICAL CANCER RESEARCH
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
- (2018) Chuanyao Cheng et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
- (2018) Songlin Liu et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Matrine reversed multidrug resistance of breast cancer MCF-7/ADR cells through PI3K/AKT signaling pathway
- (2018) Bing-Gang Zhou et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry
- (2018) Md. Mamunur Rashid et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
- (2018) Jianbiao Zhou et al. Journal of Hematology & Oncology
- Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex
- (2018) Shan Gao et al. MEDICINE
- The mTOR–S6K pathway links growth signalling to DNA damage response by targeting RNF168
- (2018) Xiaoduo Xie et al. NATURE CELL BIOLOGY
- The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- (2018) Yu-Ru Lee et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- OUP accepted manuscript
- (2018) NUCLEIC ACIDS RESEARCH
- Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
- (2018) Timothy McKinnon et al. ONCOGENE
- MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN
- (2018) Julia Ramírez-Moya et al. ONCOGENE
- Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway
- (2018) Ramón García-Escudero et al. ORAL ONCOLOGY
- RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer
- (2018) Said El Shamieh et al. PHARMACOGENOMICS
- Interest of next-generation sequencing in BCG-treated high-risk bladder cancer
- (2018) C. Jungels et al. PROGRES EN UROLOGIE
- The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth
- (2018) Jianjun Zhang et al. Science Signaling
- PDK1: At the crossroad of cancer signaling pathways
- (2018) Paolo Armando Gagliardi et al. SEMINARS IN CANCER BIOLOGY
- Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
- (2018) Dongshao Chen et al. Cell Death & Disease
- Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
- (2018) Li Chen et al. Nature Communications
- Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
- (2018) Arnon P. Kater et al. Blood Cancer Journal
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
- (2018) Ning Wu et al. Journal of Cancer
- The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth
- (2018) Jianjun Zhang et al. Science Signaling
- Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
- (2018) Xiaoxiao Wang et al. NEOPLASIA
- PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue
- (2018) Tomoya Yokota et al. BMC CANCER
- Regulation of PTEN expression by noncoding RNAs
- (2018) Wang Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
- (2018) Claudia Brandt et al. NEUROPHARMACOLOGY
- HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
- (2018) Shixiu Sun et al. Cell Death & Disease
- IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
- (2018) Jonatan Zorea et al. Cell Death & Disease
- MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN
- (2018) Hui Lin et al. Scientific Reports
- Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency
- (2018) Anida Hasanovic et al. Cells
- Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
- (2018) Silvia L. Locatelli et al. CLINICAL CANCER RESEARCH
- Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
- (2018) Sarah P Blagden et al. CLINICAL CANCER RESEARCH
- Long noncoding RNA OIP5‐AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR‐340‐5p
- (2018) Lei Song et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly
- (2018) Lara Rodriguez-Laguna et al. JOURNAL OF EXPERIMENTAL MEDICINE
- mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
- (2018) Stacia L. Koppenhafer et al. MOLECULAR CANCER THERAPEUTICS
- MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers
- (2018) Stephanie L. Fricke et al. MOLECULAR CANCER THERAPEUTICS
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer
- (2018) Sheng Chen et al. Cell Death & Disease
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
- (2017) Paula Fontes Asprino et al. ENDOCRINE-RELATED CANCER
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- miR-103 Promotes Proliferation and Metastasis by Targeting KLF4 in Gastric Cancer
- (2017) Jie Zheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Analysis of TSC1 mutation spectrum in mucosal melanoma
- (2017) Meng Ma et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
- (2017) Shanshan Zhang et al. JOURNAL OF HEPATOLOGY
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
- (2017) Paul A. VanderLaan et al. LUNG CANCER
- Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
- (2017) Ümmügülsüm Yesilöz et al. NEURO-ONCOLOGY
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- (2017) T Fujishita et al. ONCOGENE
- Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway
- (2017) Jiumao Lin et al. ONCOLOGY REPORTS
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
- (2017) Elisa Oricchio et al. Science Translational Medicine
- A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
- (2017) Trisha M. Wise-Draper et al. Targeted Oncology
- Combined treatment of pancreatic cancer xenograft with 90Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
- (2017) Winn Aung et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- The genomic landscape of tuberous sclerosis complex
- (2017) Katie R. Martin et al. Nature Communications
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer
- (2017) Karina J. Matissek et al. Cancer Discovery
- Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
- (2017) King Xin Koh et al. Oncotarget
- PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
- (2017) Liyan Chen et al. Oncotarget
- Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
- (2017) Anas Younes et al. HAEMATOLOGICA
- Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
- (2017) Masayuki Yamaji et al. Cancer Medicine
- MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway
- (2017) Yuan Miao et al. Scientific Reports
- Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
- (2016) Ashish Kulkarni et al. ACS Nano
- Rapamycin-insensitive companion of mTOR ( RICTOR ) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 Inhibition
- (2016) S. T. Kim et al. ANNALS OF ONCOLOGY
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2016) Sarah K. Tasian et al. BLOOD
- Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
- (2016) R. Thijssen et al. BLOOD
- PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- (2016) Angel Guerrero-Zotano et al. CANCER AND METASTASIS REVIEWS
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
- (2016) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
- (2016) D. J. Kwiatkowski et al. CLINICAL CANCER RESEARCH
- TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication
- (2016) Daniel W H Ho et al. GUT
- The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells
- (2016) Haiying Wang et al. Hematology
- The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
- (2016) Timothy P. Heffron et al. JOURNAL OF MEDICINAL CHEMISTRY
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer
- (2016) Fernanda Musa et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
- (2016) M. C. Smith et al. MOLECULAR CANCER THERAPEUTICS
- Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling
- (2016) L Du et al. ONCOGENE
- Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth
- (2016) Y Wang et al. ONCOGENE
- The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
- (2016) Ismael Riquelme et al. PATHOLOGY & ONCOLOGY RESEARCH
- AKT1E17K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
- (2016) Donatella Malanga et al. PLoS One
- Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers
- (2016) Babak Alaei-Mahabadi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2
- (2016) Yong-Bin Zheng et al. Oncology Letters
- A genetic basis for the variation in the vulnerability of cancer to DNA damage
- (2016) Brian D. Yard et al. Nature Communications
- Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
- (2016) Maria L. Mancini et al. Oncotarget
- Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer
- (2016) Romana Moench et al. Oncotarget
- Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
- (2016) Sun Min Lim et al. Oncotarget
- Association ofMTORMutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
- (2016) Ghayda M. Mirzaa et al. JAMA Neurology
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer
- (2016) Si-Hyong Jang et al. Journal of Gastric Cancer
- Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers
- (2015) Bernard Barlaam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescencein situhybridization impact on prognosis in breast cancer
- (2015) Jiao Li et al. CANCER SCIENCE
- Taselisib (GDC-0032), a Potent -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
- (2015) Z. S. Zumsteg et al. CLINICAL CANCER RESEARCH
- Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
- (2015) C. P. Hall et al. CLINICAL CANCER RESEARCH
- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
- (2015) Ursula Matulonis et al. GYNECOLOGIC ONCOLOGY
- Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines
- (2015) Laura Lattanzio et al. INVESTIGATIONAL NEW DRUGS
- The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
- (2015) Zhi Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease
- (2015) Kenneth Down et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers
- (2015) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy
- (2015) Maddalena Mognato et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
- (2015) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Akt-Mediated Phosphorylation of XLF Impairs Non-Homologous End-Joining DNA Repair
- (2015) Pengda Liu et al. MOLECULAR CELL
- MAGI3–AKT3 fusion in breast cancer amended
- (2015) Juan-Miguel Mosquera et al. NATURE
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- RecurrentBCAM-AKT2fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma
- (2015) Kalpana Kannan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The butterfly effect in cancer: A single base mutation can remodel the cell
- (2015) Jonathan R. Hart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
- (2015) Haluk Yuzugullu et al. Nature Communications
- RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
- (2015) H. Cheng et al. Cancer Discovery
- Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
- (2015) Xiao-jun Qian et al. Oncotarget
- Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
- (2015) Arindam P. Ghosh et al. Oncotarget
- Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis
- (2015) Elizabeth L. Yanik et al. Cancer Medicine
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
- (2014) Claudia Fumarola et al. BIOCHEMICAL PHARMACOLOGY
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis
- (2014) Wenjia Wang et al. BMC CANCER
- Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway
- (2014) Hua Sui et al. BMC Complementary and Alternative Medicine
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
- (2014) Sara Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
- (2014) V D'Amato et al. BRITISH JOURNAL OF CANCER
- Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
- (2014) Eva Maria Ciruelos Gil CANCER TREATMENT REVIEWS
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations
- (2014) A. D. Bucheit et al. CLINICAL CANCER RESEARCH
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
- (2014) T. A. Yap et al. CLINICAL CANCER RESEARCH
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex
- (2014) Heung-Mo Yang et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab
- (2014) Alexandre A. B. A. da Costa et al. International Journal of Clinical Oncology
- PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
- (2014) Prabhakar Mithal et al. INTERNATIONAL JOURNAL OF UROLOGY
- Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer
- (2014) Jun Qin et al. JOURNAL OF CLINICAL INVESTIGATION
- Milestones in the Use of Combined-Modality Radiation Therapy and Chemotherapy
- (2014) Theodore S. Lawrence et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
- (2014) Timothy D. Cushing et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2014) Pasi A. Jänne et al. Journal of Thoracic Oncology
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer
- (2014) Benjamin Levy et al. Journal of Thoracic Oncology
- Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
- (2014) Kyriakos P. Papadopoulos et al. LEUKEMIA & LYMPHOMA
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer
- (2014) Qing-Ying Zhang et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
- (2014) Pengda Liu et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma
- (2014) Qiang Xie et al. NEUROPATHOLOGY
- AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake
- (2014) Ramachandran Rashmi et al. PLoS One
- The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression
- (2014) Khalil A. Choucair et al. Translational Oncology
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
- (2014) Paraskevi Gkeka et al. PLoS Computational Biology
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients
- (2013) Wei-feng Wang et al. ACTA PHARMACOLOGICA SINICA
- Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers
- (2013) Ju-yeon Jeong et al. APOPTOSIS
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- Where Birt–Hogg–Dubé meets Cowden Syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours
- (2013) Laura Maria Pradella et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Birt–Hogg–Dubé syndrome is a novel ciliopathy
- (2013) Monique N.H. Luijten et al. HUMAN MOLECULAR GENETICS
- Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
- (2013) Ryan P. P. Shugg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ActivatingAKT2Mutation: Hypoinsulinemic Hypoketotic Hypoglycemia
- (2013) Ved Bhushan Arya et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
- (2013) Jing Li et al. Journal of Translational Medicine
- Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential
- (2013) L M Neri et al. LEUKEMIA
- A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells
- (2013) Per Johnsson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies
- (2013) R Vander Broek et al. ORAL DISEASES
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- MiR-424/503-Mediated Rictor Upregulation Promotes Tumor Progression
- (2013) Chitose Oneyama et al. PLoS One
- A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
- (2013) B. D. Hopkins et al. SCIENCE
- AKT Facilitates EGFR Trafficking and Degradation by Phosphorylating and Activating PIKfyve
- (2013) E. E. Er et al. Science Signaling
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
- (2013) Mi Kwon Son et al. Scientific Reports
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer
- (2012) Jing Shi et al. BMC CANCER
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
- (2012) Mary Maluccio et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis
- (2012) Hyunseung Lee et al. CANCER LETTERS
- High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation
- (2012) Niki Tzenaki et al. FASEB JOURNAL
- Genetic disruption of the PI3K regulatory subunits, p85 , p55 , and p50 , normalizes mutant PTPN11-induced hypersensitivity to GM-CSF
- (2012) C. B. Goodwin et al. HAEMATOLOGICA
- PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma
- (2012) Azusa Abe et al. HUMAN PATHOLOGY
- PI3K-independent AKT activation in cancers: A treasure trove for novel therapeutics
- (2012) Kiran Mahajan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
- (2012) Justin Cidado et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
- (2012) Vassiliki Papadimitrakopoulou Journal of Thoracic Oncology
- Sequence analysis of mutations and translocations across breast cancer subtypes
- (2012) Shantanu Banerji et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
- (2012) Jing Ni et al. Cancer Discovery
- Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors
- (2011) Deborah S. Mortensen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
- (2011) Didier Roulin et al. Molecular Cancer
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome
- (2011) Marjorie J. Lindhurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion
- (2011) Y Gu et al. ONCOGENE
- Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling
- (2011) C Garofalo et al. ONCOGENE
- Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination
- (2011) H. Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells
- (2010) Fengxue Zhang et al. CANCER BIOLOGY & THERAPY
- B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer
- (2010) Jing Tan et al. CANCER CELL
- Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway
- (2010) Lijun He et al. CANCER SCIENCE
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions
- (2010) John M.S. Bartlett Clinical Breast Cancer
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
- (2010) P. Wu et al. CURRENT MEDICINAL CHEMISTRY
- Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
- (2010) Sauveur-Michel Maira et al. Future Medicinal Chemistry
- ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
- (2010) Audrey Carriere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PTEN mutation spectrum in breast cancers and breast hyperplasia
- (2010) JuLun Yang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
- (2010) Sara M. Johnson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer
- (2010) Benjamin Solomon et al. Journal of Thoracic Oncology
- MEK1 and AKT2 Mutations in Japanese Lung Cancer
- (2010) Hidefumi Sasaki et al. Journal of Thoracic Oncology
- Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
- (2010) Christina Barbara Ching et al. LABORATORY INVESTIGATION
- Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction
- (2010) Daming Gao et al. MOLECULAR CELL
- A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
- (2010) Laura Poliseno et al. NATURE
- Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
- (2010) J Lauring et al. ONCOGENE
- Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
- (2010) Wen-I Wu et al. PLoS One
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Up-regulation of PIK3CA promotes metastasis in gastric carcinoma
- (2010) Ji-Fang Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- The Methylation of the TSC2 Promoter Underlies the Abnormal Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells
- (2009) Elena Lesma et al. AMERICAN JOURNAL OF PATHOLOGY
- Evidence-Based Surgical Care and the Evolution of Fast-Track Surgery
- (2009) Henrik Kehlet et al. ANNALS OF SURGERY
- Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma
- (2009) R. Hino et al. CANCER RESEARCH
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Oncogenic Ras, but not V600EB-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells
- (2009) L. Calleros et al. CARCINOGENESIS
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
- (2009) Todd Morgan et al. CURRENT CANCER DRUG TARGETS
- Emerging common themes in regulation of PIKKs and PI3Ks
- (2009) Harri Lempiäinen et al. EMBO JOURNAL
- The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
- (2009) J. T. Huse et al. GENES & DEVELOPMENT
- Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma
- (2009) Akagi INTERNATIONAL JOURNAL OF ONCOLOGY
- The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells
- (2009) Li-Bing Song et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma
- (2008) Sanjukta Chakraborty et al. BMC CANCER
- Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival
- (2008) Hirozumi Sawai et al. BMC GASTROENTEROLOGY
- A novel AKT3 mutation in melanoma tumours and cell lines
- (2008) M A Davies et al. BRITISH JOURNAL OF CANCER
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling
- (2008) M. P. DeYoung et al. GENES & DEVELOPMENT
- Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells
- (2008) Masao Fujiwara et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers
- (2008) Q Zhu et al. ONCOGENE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex
- (2008) T. K. Neklesa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now